Ładuje się......
Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo
Combination therapy concurrently targeting PD1 and CTLA4 immune checkpoints leads to remarkable anti-tumor effects. While both PD1 and CTLA4 dampen the T cell activation, the in vivo effects of these drugs in humans remain to be clearly defined. In order to better understand biologic effects of ther...
Zapisane w:
| Wydane w: | J Immunol |
|---|---|
| Główni autorzy: | , , , , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2014
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4380504/ https://ncbi.nlm.nih.gov/pubmed/25539810 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1401686 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|